The pediatric oncology condition center is a comprehensive resource for clinical news and expert insights on pediatric oncology. Read more at OncLive.
June 11th 2025
Data from the phase 1 CLOVER-2 trial demonstrated the safety and activity of iopofosine I-131 in relapsed/refractory pediatric high-grade glioma.
May 23rd 2025
The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.
May 22nd 2025
Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.
May 21st 2025
Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.
May 7th 2025
The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.
April 10th 2025
The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.
April 4th 2025
Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.
March 6th 2025
Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.
February 21st 2025
Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.
February 16th 2025
The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.
February 15th 2025
Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.
February 11th 2025
The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.
February 3rd 2025
Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
January 24th 2025
The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.
December 18th 2024
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.